NCT01319422View on ClinicalTrials.gov

Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Multiple Myeloma
Interventions
DRUG

Pomalidomide

Comparison of different dosages and schedules of drug

Trial Locations (1)

06520

Yale University, New Haven

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Yale University

OTHER

NCT01319422 - Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter